News coverage about CryoPort (NASDAQ:CYRX) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CryoPort earned a news impact score of 0.23 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.6116577104089 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of CryoPort (CYRX) traded up 2.20% during mid-day trading on Friday, hitting $8.35. The stock had a trading volume of 25,511 shares. The firm has a 50 day moving average of $8.68 and a 200-day moving average of $5.41. CryoPort has a one year low of $1.80 and a one year high of $10.40. The stock’s market cap is $206.03 million.
CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, August 8th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $2.92 million for the quarter, compared to the consensus estimate of $2.84 million. CryoPort had a negative return on equity of 67.75% and a negative net margin of 102.89%. Equities research analysts expect that CryoPort will post ($0.72) earnings per share for the current fiscal year.
A number of research analysts recently commented on the company. Janney Montgomery Scott boosted their price target on CryoPort from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, October 3rd. Cowen and Company reaffirmed an “outperform” rating and set a $11.00 price objective (up from $7.50) on shares of CryoPort in a report on Tuesday, September 12th. Finally, Needham & Company LLC upped their price objective on CryoPort from $8.50 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, August 30th.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with MarketBeat.com's FREE daily email newsletter.